National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 monoclonal antibody BrE-3
A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:BrE-3 monoclonal antibody, yttrium Y 90
MOAB BrE-3, yttrium Y 90
Y90 monoclonal antibody BrE-3
Abbreviation:Y90 MOAB BrE-3



Previous:yttrium Y 90 DOTA monoclonal antibody HuPAM4, yttrium Y 90 glass microspheres, yttrium Y 90 humanized epratuzumab, yttrium Y 90 ibritumomab tiuxetan, yttrium Y 90 monoclonal antibody B3
Next:yttrium Y 90 monoclonal antibody Hu3S193, yttrium Y 90 monoclonal antibody MN-14, yttrium Y 90 resin microspheres, yttrium Y 90-DOTA-chimeric monoclonal antibody cG250, yttrium Y 90-edotreotide

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov